Vertex Pharmaceuticals Incorporated with ticker code (VRTX) have now 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $559.00 and $325.00 and has a mean share price target at $441.83. (at the time of writing). Given that the stocks previous close was at $433.38 this indicates there is a potential upside of 1.9%. The 50 day MA is $399.08 and the 200 moving average now moves to $361.95. The company has a market cap of 111.80B. The stock price for the company is currently $433.87 USD
The potential market cap would be $113,980,809,512 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 32.57, revenue per share of $37.49 and a 14.34% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
